Fluxion Biosciences, a developer of automated solutions for cellular analysis in life sciences research and drug discovery, has signed a distribution agreement with Harvard Bioscience. The agreement covers Fluxion’s BioFlux and IonFlux platforms for sale to Harvard Bioscience’s customers in North America.

The BioFlux system is used by researchers for automated, high throughput studies of cell-cell interactions, and complements Harvard Bio’s existing perfusion systems. The IonFlux system is used by pharmaceutical companies and academic labs for ion channel research and drug discovery.

“We are delighted to distribute Fluxion’s IonFlux and BioFlux Systems,” said John Battista, North American Sales Director for Electrophysiology Products at Harvard Bioscience. “IonFlux is a perfect fit with our other electrophysiology products, and extends our capabilities to high throughput automated analysis. Similarly, the BioFlux System is a natural extension of our well-established Warner Instruments flow cell portfolio, permitting higher-throughput, microfluidic processing of eukaryotic and bacterial assays under flow.”